Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response

Ronde, Jorma J. de; Hannemann, Juliane; Halfwerk, Hans; Mulder, Lennart; Straver, Marieke E.; Peeters, Marie‐Jeanne T. F. D. Vrancken; Wesseling, Jelle; Vijver, Marc J. van de; Wessels, Lodewyk; Rodenhuis, S.

doi:10.1007/s10549-009-0499-6

Cited by 150 publications

(104 citation statements)

References 39 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conversely, all tumors with HER2 amplification or overexpression are not included in the HER2 cluster by microarray analysis [39,40] . Staaf et al [41] identified three separate subtypes of HER2-positive tumors, one with a clearly poor prognosis with a 12% 10 year survival compared to the 50-55% survival in the other two groups using HER2 derived prognostic predictor (HDPP) gene analysis.…”

Section: Her2-positivementioning

confidence: 99%

Biological subtypes of breast cancer: Prognostic and therapeutic implications

Yersal

Barutça

2014

WJCO

824

578

View full text Add to dashboard Cite

show abstract

Section: Her2-positivementioning

confidence: 99%

Biological subtypes of breast cancer: Prognostic and therapeutic implications

Yersal

Barutça

2014

WJCO

824

578

View full text Add to dashboard Cite

show abstract

“…Intrinsically different subtypes of breast cancer have been identified in the past years based on gene expression profiles and immunohistochemical (IHC) localization of selected targets which might influence the responsiveness to preoperative therapies and the outcome after surgery [9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features

Montagna

Bagnardi

Rotmensz

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

“…Geliştirilen moleküler teknikler yardımıyla günü-müzde, farklı onkogen/pro-onkogen aktivasyonu ve/ veya tümör süpresör gen fonksiyonlarında kayıplara bağlı olarak, histopatolojik görünümleri aynı bile olsa tümörlerin farklı davranış, tedavi yanıtı ve prognoz gösterdikleri anlaşılmıştır (7)(8)(9) . Özetle günümüzde cErbB-2, p53, Ki67, ER ve PR benzeri çeşitli belirleyicilerin, meme kanserinin prognozunu öngörmede ve tedavi şeklini belirlemede yol gösterici olduğu anlaşılmıştır (15)(16)(17)(18)(19)(20)(21) .…”

Section: Discussionunclassified

“…Buna karşı- lık moleküler alt tip ile histolojik derece ilişkili bulunmuş olup, literatürle uyumlu olarak luminal A gruptaki tümörlerin en düşük histolojik dereceli oldukları gözlenmiştir (p=0,004). Aksiller lenf noduna yayılım olması meme kanserinde metastazdan sonra en önemli prognostik faktör-dür (5)(6)(7)(8)(9)(10)(11) . Çalışmamızda aksiller lenf noduna yayılım olan hastaların 24-aylık genel sağkalımı %85,7 iken, aksiller lenf nodu yayılımı olmayan hastaların %97,4 olduğu tespit edildi ve aradaki farklılık istatistiksel olarak anlamlı bulundu (p=0,047).…”

Section: Discussionunclassified

“…Epidemiyolojik çalışmalarda prevalansı %22-26, meme kanserine bağlı mortalite riski ise %18 dolayındadır (3,4) . Malign meme tümörlerinin sınıflaması geleneksel olarak histolojik görünümüne göre yapılmaktayken, günümüz-de moleküler özelliklerine göre bazı alt tipler tanım-lanmıştır (5)(6)(7)(8) . İlk kez 2000 yılında Perou ve ark.…”

Section: Introductionunclassified

See 1 more Smart Citation

Evaluation Of Clinicopathological Features Of Breast Cancer According To The Molecular Subtypes

Uncel¹,

Aköz²,

Yıldırım³

et al. 2015

Terh

View full text Add to dashboard Cite

ÖZETAmaç: Meme kanseri dünyada kadınlarda en sık gözlenen malignitedir. Meme kanseri, histolojik olarak benzer ve aynı evredeki tümörlerde bile farklı tedavi yanıtı sergileyen heterojen bir tümördür. Bu çalışmada meme kanserinin klinik ve patolojik özelliklerini, tümörün moleküler alt tiplerine göre karşılaştırmayı amaçladık. Results: A total of 292 females with invasive breast cancer were included in this study. The mean age of the patients was 55.5±12.8 years (28-85 years) which was similar to mean ages of patients with different tumor types. We identified 90 (30.8%) cases of luminal A, 87 (29.8%) luminal B, 78 (26.7%) HER2+, and 37 (12.7%) triple negative. The mean Ki-67 proliferation index was found to be 5 (1-12) in Luminal A group, in Luminal B group, in Her2 positive group and 43 (1-85) in triple negative group. The mean follow-up period was 22.5±10.9 months. Mean mortality rate was found as 10.6% (n = 31) in all patients. The least survival rate was determined in triple negative patients (78.4%, n=29). The highest survival rate was assessed (as compatible with the literature) in the luminal A group (n= 83, 92.2%). HER2-positive cases had second highest survival rate with tailored treatment (n= 71, 91%). Conclusion: Histopathologic features or histological grade of breast cancer alone are not reliable prognostic factors. It must be always considered that breast cancer is a heterogeneous tumor. Therefore in breast cancer, tailored therapy according to the molecular subtypes of tumor, seems to provide the highest benefit for patients.

show abstract

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response

Cited by 150 publications

References 39 publications

Biological subtypes of breast cancer: Prognostic and therapeutic implications

Biological subtypes of breast cancer: Prognostic and therapeutic implications

Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features

Evaluation Of Clinicopathological Features Of Breast Cancer According To The Molecular Subtypes

Contact Info

Product

Resources

About